Entrada Therapeutics Stock Performance
| TRDA Stock | USD 6.26 0.12 1.88% |
The firm shows a Beta (market volatility) of 1.85, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Entrada Therapeutics will likely underperform. At this point, Entrada Therapeutics has a negative expected return of -0.31%. Please make sure to confirm Entrada Therapeutics' rate of daily change, and the relationship between the kurtosis and market facilitation index , to decide if Entrada Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Entrada Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's fundamental indicators remain somewhat strong which may send shares a bit higher in August 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (1.88) | Five Day Return (3.69) | Year To Date Return (64.15) | Ten Year Return (73.86) | All Time Return (73.86) |
1 | Entrada Therapeutics, Inc. Reports Q1 Loss, Tops Revenue Estimates | 05/08/2025 |
2 | Disposition of 1800 shares by Dipal Doshi of Entrada Therapeutics at 15.0 subject to Rule 16b-3 | 05/13/2025 |
3 | Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 12 Multiple Ascending Dose Clinical Study of ENTR-601-45 i... | 05/28/2025 |
4 | Insider Trading | 05/30/2025 |
5 | Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 06/02/2025 |
6 | Disposition of 17566 shares by Dipal Doshi of Entrada Therapeutics at 11.6786 subject to Rule 16b-3 | 06/04/2025 |
7 | Transcript Entrada Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - marketscreener.com | 06/09/2025 |
8 | Acquisition by Chapman Gina of 19000 shares of Entrada Therapeutics at 7.9 subject to Rule 16b-3 | 06/11/2025 |
9 | Long Term Investment Analysis - news.stocktradersdaily.com | 06/17/2025 |
10 | Disposition of 6422 shares by 5am Ventures V, L.p. of Entrada Therapeutics at 6.8127 subject to Rule 16b-3 | 06/30/2025 |
11 | Entrada Therapeutics, Inc. Major Shareholder Ventures V. L.P. 5Am Sells 19,265 Shares | 07/02/2025 |
12 | Ventures V. L.P. 5Am Sells 6,422 Shares of Entrada Therapeutics, Inc. Stock | 07/03/2025 |
13 | Disposition of 6935 shares by 5am Ventures V, L.p. of Entrada Therapeutics at 7.502 subject to Rule 16b-3 | 07/09/2025 |
14 | Entrada therapeutics director Parmar sells 202k in stock - Investing.com | 07/11/2025 |
15 | Disposition of 6422 shares by Parmar Kush of Entrada Therapeutics at 7.1226 subject to Rule 16b-3 | 07/14/2025 |
| Begin Period Cash Flow | 71.6 M | |
| Total Cashflows From Investing Activities | -27.8 M |
Entrada Therapeutics Relative Risk vs. Return Landscape
If you would invest 795.00 in Entrada Therapeutics on April 21, 2025 and sell it today you would lose (169.00) from holding Entrada Therapeutics or give up 21.26% of portfolio value over 90 days. Entrada Therapeutics is currently does not generate positive expected returns and assumes 3.6638% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Entrada, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Entrada Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Entrada Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Entrada Therapeutics, and traders can use it to determine the average amount a Entrada Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0851
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TRDA |
Estimated Market Risk
| 3.66 actual daily | 32 68% of assets are more volatile |
Expected Return
| -0.31 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Entrada Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Entrada Therapeutics by adding Entrada Therapeutics to a well-diversified portfolio.
Entrada Therapeutics Fundamentals Growth
Entrada Stock prices reflect investors' perceptions of the future prospects and financial health of Entrada Therapeutics, and Entrada Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Entrada Stock performance.
| Return On Equity | 0.0722 | ||||
| Return On Asset | 0.0051 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | (1.06) % | ||||
| Current Valuation | (87.93 M) | ||||
| Shares Outstanding | 37.95 M | ||||
| Price To Book | 0.57 X | ||||
| Price To Sales | 1.38 X | ||||
| Revenue | 210.78 M | ||||
| Gross Profit | 43.45 M | ||||
| EBITDA | 47.01 M | ||||
| Net Income | 65.63 M | ||||
| Cash And Equivalents | 244.25 M | ||||
| Cash Per Share | 7.81 X | ||||
| Total Debt | 59.21 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 14.05 X | ||||
| Book Value Per Share | 11.84 X | ||||
| Cash Flow From Operations | (41.56 M) | ||||
| Earnings Per Share | 0.58 X | ||||
| Market Capitalization | 237.59 M | ||||
| Total Asset | 526.32 M | ||||
| Retained Earnings | (129.34 M) | ||||
| Working Capital | 400.56 M | ||||
About Entrada Therapeutics Performance
By analyzing Entrada Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Entrada Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Entrada Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Entrada Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.12 | 0.13 | |
| Return On Capital Employed | 0.10 | 0.10 | |
| Return On Assets | 0.12 | 0.13 | |
| Return On Equity | 0.15 | 0.09 |
Things to note about Entrada Therapeutics performance evaluation
Checking the ongoing alerts about Entrada Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Entrada Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Entrada Therapeutics generated a negative expected return over the last 90 days | |
| Entrada Therapeutics has high historical volatility and very poor performance | |
| Entrada Therapeutics currently holds about 244.25 M in cash with (41.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.81, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 80.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Entrada therapeutics director Parmar sells 202k in stock - Investing.com |
- Analyzing Entrada Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Entrada Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Entrada Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Entrada Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Entrada Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Entrada Therapeutics' stock. These opinions can provide insight into Entrada Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Entrada Stock analysis
When running Entrada Therapeutics' price analysis, check to measure Entrada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entrada Therapeutics is operating at the current time. Most of Entrada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Entrada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entrada Therapeutics' price. Additionally, you may evaluate how the addition of Entrada Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Stocks Directory Find actively traded stocks across global markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |